Greater clinical benefit for patients with brain disorders and gains in cost-effectiveness for society – both can be achieved by earlier intervention, closer co-ordination of multidisciplinary care, and disseminating best practices in treatment. Parkinson’s Disease, Alzheimer’s Disease and schizophrenia are among the areas considered in detail by the European Brain Council’s Value of Treatment initiative.